These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18592956)

  • 1. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 9. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic effects of rimonabant: clinical implications.
    Després JP
    Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Special report on the Sanofi-Aventis cardiometabolic symposium.
    Cardiovasc J Afr; 2007; 18(3):192-5, 198-200, 202. PubMed ID: 17612757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.